RUBYnanomed

RUBYnanomed is rated 3 out of 5 in the category non-invasive monitoring of cancer progression. Read and write reviews about RUBYnanomed. RUBYnanomed was founded in 2018 and aims to bring lab discoveries to the clinical market. RUBYnanomed focusses on the non-invasive monitoring of cancer progression, as cancer is a major cause of death worldwide that caused 9.6 million deaths in 2018, and 90 % of those are due to metastasis. We have developed a precise cancer snapshot tool, the RUBYchipTM, a microfluidic device for isolating all types of circulating tumour cells (CTCs) from unprocessed whole blood. Currently, RUBYnanomed is running pre-clinical trials at 8 hospitals for 5 different types of cancer in different countries in Europe.